Overview

Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma

Status:
Active, not recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

This is a phase II study of the combination of radiation therapy, temozolomide and Avastin followed by Avastin, temozolomide, and topotecan in grade IV malignant glioma patients.

Phase:

Phase 2

Details

Lead Sponsor:

Duke University

Collaborators:

Genentech, Inc.
GlaxoSmithKline

Treatments:

Bevacizumab
Dacarbazine
Temozolomide
Topotecan